Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016-1Q2021

M. CHAPPUY ; M. NOURREDINE ; B. CLERC ; M. FAHMI ; P. MISSLIN ; M. BERTHIER ; L. LALOI ; B. ROLLAND | 2022
Dans Fundamental and Clinical Pharmacology (Vol.36, n°2, April 2022) Article : Périodique

BACKGROUND: Gabapentinoids (i.e., gabapentin and pregabalin) are medications approved for epilepsy, chronic pain, or generalized anxiety disorder. Recently, there have been regular reports of misuse of pregabalin, and to a lesser extent, gabapen[...]

Plus d'info

Ajouter à la sélection

Lien externe